The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer

Roger Li; Seth P Lerner; Ashish M Kamat

doi:10.1016/j.eururo.2021.01.001

The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer

Eur Urol. 2021 Apr;79(4):437-439. doi: 10.1016/j.eururo.2021.01.001. Epub 2021 Jan 14.

Authors

Roger Li¹, Seth P Lerner², Ashish M Kamat³

Affiliations

¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: roger.li@moffitt.org.
² Scott Department of Urology, Baylor College of Medicine, Dan L. Duncan Cancer Center, Houston, TX, USA.
³ Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.

PMID: 33454163
DOI: 10.1016/j.eururo.2021.01.001

Abstract

There are several clinical scenarios that may not adhere to the precise definition of bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, but nevertheless indicate treatment unresponsiveness. We describe four such scenarios as a frame of reference in order to reach a consensus on the enrollment of such patients to current and future clinical trials in the BCG-unresponsive setting.

Publication types

Editorial

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine / adverse effects
Humans
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Urinary Bladder
Urinary Bladder Neoplasms* / drug therapy

Substances

Adjuvants, Immunologic
BCG Vaccine